SCCL
MCID: SML038
MIFTS: 68

Small Cell Cancer of the Lung (SCCL)

Categories: Cancer diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Small Cell Cancer of the Lung

MalaCards integrated aliases for Small Cell Cancer of the Lung:

Name: Small Cell Cancer of the Lung 57
Small Cell Lung Carcinoma 28 5 43 16
Small Cell Lung Cancer 19 58 75 53
Small-Cell Cancer of Lung 57 12
Lung Small Cell Carcinoma 11 14
Sclc 57 58
Small Cell Carcinoma of Lung 71
Cancer, Lung, Small Cell 38
Carcinoma, Small Cell 71
Sclc1 57
Sccl 57

Characteristics:


Inheritance:

Autosomal dominant 57

Prevelance:

Small Cell Lung Cancer: 1-5/10000 (Europe) 58

Age Of Onset:

Small Cell Lung Cancer: Adult 58

Classifications:

Orphanet: 58  
Rare respiratory diseases


External Ids:

Disease Ontology 11 DOID:5409
OMIM® 57 182280
MeSH 43 D055752
NCIt 49 C4917
SNOMED-CT 68 254632001
ICD10 via Orphanet 32 C34.9
UMLS via Orphanet 72 C0149925
Orphanet 58 ORPHA70573
MedGen 40 C0149925
SNOMED-CT via HPO 69 126713003
UMLS 71 C0149925 C0262584

Summaries for Small Cell Cancer of the Lung

Orphanet: 58 Small cell lung cancer (SCLC) is a highly aggressive malignant neoplasm, accounting for 10-15% of lung cancer cases, characterized by rapid growth, and early metastasis. SCLC usually manifests as a large hilar mass with bulky mediastinal lymphadenopathy presenting clinically with chest pain, persistent cough, dyspnea, wheezing, hoarseness, hemoptysis, loss of appetite, weight loss, and neurological and endocrine paraneoplastic syndromes. SCLC is primarily reported in elderly people with a history of long-term tobacco exposure.

MalaCards based summary: Small Cell Cancer of the Lung, also known as small cell lung carcinoma, is related to lung squamous cell carcinoma and melanoma. An important gene associated with Small Cell Cancer of the Lung is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Endometrial cancer and Hepatocyte growth factor receptor signaling. The drugs Erlotinib and Vinblastine have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and brain, and related phenotypes are neoplasm of the lung and neoplasm

Disease Ontology: 11 A lung carcinoma that has material basis in primitive-appearing cells that are smaller than normal cells and is located in the lung.

Wikipedia: 75 Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung,... more...

More information from OMIM: 182280

Related Diseases for Small Cell Cancer of the Lung

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung Lung Clear Cell Carcinoma

Diseases related to Small Cell Cancer of the Lung via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1704)
# Related Disease Score Top Affiliating Genes
1 lung squamous cell carcinoma 32.2 TUG1 TP53 RB1 PTEN PIK3CA CCAT2
2 melanoma 31.6 TP53 RB1 PTEN PIK3CA MIR21 MALAT1
3 head and neck cancer 31.5 TP53 PTEN PIK3CA MIR21 AKT1
4 esophagus squamous cell carcinoma 31.5 TUG1 MALAT1 HOTTIP HOTAIR
5 mucinous adenocarcinoma 31.5 TP53 PIK3CA NKX2-1
6 polyploidy 31.5 TP73 TP53
7 lung large cell carcinoma 31.4 TP53 SYP NKX2-1 NCAM1 GRP ENO2
8 spinal cord disease 31.4 TP53 SYP PTEN AKT1
9 appendix adenocarcinoma 31.4 TP53 SYP CHGA
10 esophageal cancer 31.4 TP73 TP53 RB1 PTEN PIK3CA MIR21
11 osteogenic sarcoma 31.4 TUG1 TP53 RB1 MALAT1 HOTTIP HOTAIR
12 kidney cancer 31.4 TP53 PIK3CA MIR21 MALAT1 HOTAIR
13 sarcoma 31.3 TP53 RB1 PIK3CA HOTAIR ENO2
14 stroke, ischemic 31.3 PIK3CA MIR21 MALAT1 ENO2 AKT1
15 papillary adenocarcinoma 31.2 TP53 NKX2-1 MIR21
16 squamous cell carcinoma, head and neck 31.2 TP73 TP53 RB1 PTEN PIK3CA MIR21
17 retinitis pigmentosa 11 31.2 TUG1 TP53 PTEN HOTAIR CCAT2 AKT1
18 lung cancer 31.2 TUG1 TP73 TP53 SYP RB1 PTEN
19 lip and oral cavity cancer 31.2 TP53 RB1 PIK3CA MIR21
20 leukemia, acute myeloid 31.1 TUG1 TP53 PTEN PIK3CA NCAM1 MIR21
21 ovarian cancer 31.1 TUG1 TP73 TP53 RB1 PTEN PIK3CA
22 leukemia, chronic lymphocytic 31.1 TP53 PTEN NCAM1 MIR21 B2M AKT1
23 colonic benign neoplasm 31.1 TP53 PTEN PIK3CA MIR21 AKT1
24 lymphoepithelioma-like carcinoma 31.1 TP53 SYP NCAM1 ENO2
25 neurofibromatosis, type i 31.1 TP53 PTEN ENO2 AKT1
26 renal cell carcinoma, nonpapillary 31.1 TUG1 TP53 PTEN PIK3CA NKX2-1 MIR21
27 pancreatic ductal adenocarcinoma 31.1 TP53 MIR21 MALAT1 HOTTIP HOTAIR
28 glioblastoma 31.0 TUG1 TP53 RB1 PTEN PIK3CA MIR21
29 bladder cancer 31.0 TUG1 TP73 TP53 RB1 PTEN PIK3CA
30 nasopharyngeal carcinoma 31.0 TP53 PTEN PIK3CA MIR21 MALAT1 HOTAIR
31 skin carcinoma 31.0 TP53 SYP PTEN MIR21 AKT1
32 mediastinal cancer 31.0 SYP NKX2-1 NCAM1 ENO2 CHGA
33 glioma 31.0 TP53 PTEN PIK3CA MIR21 MALAT1 HOTTIP
34 mixed cell type cancer 31.0 TP53 SYP PTEN PIK3CA ENO2 CHGA
35 thyroid carcinoma, familial medullary 31.0 NKX2-1 MALAT1 GRP CHGA
36 lynch syndrome 31.0 TP53 PTEN PIK3CA AKT1
37 small cell carcinoma 31.0 TP53 SYP PTEN NKX2-1 NCAM1 GRP
38 acute promyelocytic leukemia 31.0 TP73 TP53 PTEN PIK3CA NCAM1 AKT1
39 carcinosarcoma 31.0 TP53 SYP PTEN PIK3CA
40 ovarian epithelial cancer 31.0 MALAT1 HOTAIR CCAT2
41 skin squamous cell carcinoma 30.9 TP53 PTEN MIR21 HOTAIR AKT1
42 thyroid gland medullary carcinoma 30.9 SYP NKX2-1 CHGA
43 adenoid cystic carcinoma 30.9 TP53 PTEN PIK3CA NCAM1 AKT1
44 lung oat cell carcinoma 30.9 TP53 SYP RB1 PTEN PIK3CA ENO2
45 bladder small cell carcinoma 30.9 SYP NCAM1 ENO2
46 papilloma 30.9 TP53 RB1 PTEN AKT1
47 hepatocellular carcinoma 30.9 TUG1 TP73 TP53 RB1 PTEN PIK3CA
48 pulmonary large cell neuroendocrine carcinoma 30.9 SYP NKX2-1 NCAM1 ENO2 CHGA
49 hydrocephalus 30.9 TP53 SYP PTEN NCAM1 ENO2
50 merkel cell carcinoma 30.9 SYP NKX2-1 NCAM1 ENO2 CHGA

Graphical network of the top 20 diseases related to Small Cell Cancer of the Lung:



Diseases related to Small Cell Cancer of the Lung

Symptoms & Phenotypes for Small Cell Cancer of the Lung

Human phenotypes related to Small Cell Cancer of the Lung:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm of the lung 30 HP:0100526

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Oncology:
small-cell lung cancer

Lab:
3p23-p14 chromosome deletion in tumor

Misc:
sensitive to chemotherapy and radiotherapy

Clinical features from OMIM®:

182280 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Small Cell Cancer of the Lung:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.92 AKT1 B2M NKX2-1 PIK3CA PTEN RB1
2 normal MP:0002873 9.91 AKT1 HOTTIP MALAT1 NKX2-1 PTEN RB1
3 no phenotypic analysis MP:0003012 9.81 CHGA HOTAIR HOTTIP MALAT1 NKX2-1 PIK3CA
4 nervous system MP:0003631 9.8 AKT1 B2M CHGA ENO2 GRP MALAT1
5 respiratory system MP:0005388 9.23 AKT1 ENO2 GRP NKX2-1 PTEN RB1

Drugs & Therapeutics for Small Cell Cancer of the Lung

Drugs for Small Cell Cancer of the Lung (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 763)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Erlotinib Approved, Investigational Phase 4 183319-69-9, 183321-74-6 176870
2
Vinblastine Approved Phase 4 865-21-4 241903 13342
3
Sunitinib Approved, Investigational Phase 4 557795-19-4 5329102
4
Caffeine Approved Phase 4 58-08-2 2519
5
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760
6
Ondansetron Approved, Withdrawn Phase 4 99614-02-5 4595
7
Morphine Approved, Investigational Phase 4 57-27-2 5288826
8
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
11
Cisatracurium Approved, Investigational Phase 4 96946-41-7 62887
12
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
13
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
14
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
15
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
16
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
17
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
18
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
20
Desflurane Approved Phase 4 57041-67-5 42113
21
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
22
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
23
Scopolamine Approved, Investigational Phase 4 51-34-3 153311 3000322
24
Topotecan Approved, Investigational Phase 4 123948-87-8, 119413-54-6 60699 60700
25
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
26
Vemurafenib Approved Phase 4 918504-65-1 42611257
27
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
29
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
30
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
31
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
32
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
33
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
34
Rivoceranib Investigational Phase 4 811803-05-1 11315474
35
Flurbiprofen axetil Investigational Phase 4 91503-79-6
36 Neurotransmitter Agents Phase 4
37 Psychotropic Drugs Phase 4
38 Pharmaceutical Solutions Phase 4
39 Hypnotics and Sedatives Phase 4
40 Anesthetics Phase 4
41 Phosphodiesterase Inhibitors Phase 4
42 Endostar protein Phase 4
43 Central Nervous System Stimulants Phase 4
44 N-Methylaspartate Phase 4
45 Anti-Anxiety Agents Phase 4
46 Anesthetics, Intravenous Phase 4
47 Anesthetics, General Phase 4
48 GABA Modulators Phase 4
49 Diphosphonates Phase 4
50
bilirubin Phase 4 635-65-4 5280352

Interventional clinical trials:

(show top 50) (show all 6077)
# Name Status NCT ID Phase Drugs
1 Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride in in Combination With EC/EP Unknown status NCT03890055 Phase 4 Anlotinib Hydrochloride
2 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
3 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
4 Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin)
5 A Multicenter, Randomized, Open-label, Parallel-group Study of Paclitaxel Liposome and Cisplatin Compared With Gemcitabine and Cisplatin as First-line Therapy in Advanced Squamous Non-Small-Cell Lung Cancer Unknown status NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
6 Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen: A Prospective, Open, One-arm Clinical Study Unknown status NCT03792503 Phase 4 Apatinib;Pemetrexed
7 A Phase Ⅳ,Open,Multicenter,Single Arm Study to Evaluate the Efficacy of the Combination Conmana With Thalidomide in Patients With NSCLC(Non-Small-Cell-Lung-Cancer) Unknown status NCT02778893 Phase 4 Conmana;Thalidomide
8 Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study Unknown status NCT02480634 Phase 4 Zoledronic acid
9 Evaluation of the Efficacy of Domestic Gefitinib Tablets in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Using a Multicenter, Randomized, Positive Drug Gefitinib Pharmacodynamics and Pharmacodynamics Unknown status NCT03264794 Phase 4 Gefitinib Tab (CTTQ),First medication;Gefitinib Tab (CTTQ),From the 8th day of trial;Gefitinib tablets (Yi Ruisha),First medication;Gefitinib Tab 250 MG(CTTQ),From the 8th day of trial.
10 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
11 A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
12 High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study Unknown status NCT02404675 Phase 4 icotinib
13 The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) ) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
14 A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
15 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
16 A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
17 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
18 An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation Unknown status NCT01646450 Phase 4 Icotinib
19 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy
20 Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
21 A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients Completed NCT00608868 Phase 4 Gefitinib
22 Safety Study of Nivolumab for Selected Advanced Malignancies in India Completed NCT03444766 Phase 4 Nivolumab
23 ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study Completed NCT03550482 Phase 4
24 Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
25 A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy Completed NCT00770588 Phase 4 Gefitinib;Placebo
26 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
27 Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer Completed NCT03092986 Phase 4 Paclitaxel;Carboplatin;Cisplatin;Vinblastine Sulfate
28 A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Osimertinib in Indian Adult Patients With Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC). Completed NCT03853551 Phase 4 Osimertinib
29 A Phase III/IV, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (TAIL) Completed NCT03285763 Phase 4 Atezolizumab
30 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
31 Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
32 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
33 A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis Completed NCT00099541 Phase 4 zoledronic acid
34 An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
35 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
36 Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response Completed NCT03655834 Phase 4 Pemetrexed
37 An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer Completed NCT00949910 Phase 4 Erlotinib
38 Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
39 A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations Completed NCT02514174 Phase 4 Afatinib
40 Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
41 Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
42 A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy Completed NCT01230710 Phase 4 Erlotinib
43 A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
44 SINGLE-ARM STUDY TO EVALUATE THE SAFETY OF LORLATINIB IN ALK INHIBITOR-TREATED UNRESECTABLE ADVANCED AND/OR RECURRENT ALK-POSITIVE NON-SMALL CELL LUNG CANCER PARTICIPANTS IN INDIA Completed NCT04541706 Phase 4 Lorlatinib
45 A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Completed NCT01287754 Phase 4 erlotinib [Tarceva]
46 A Phase 3b/4 Safety Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer Completed NCT02869789 Phase 4 Nivolumab in combination with Ipilimumab
47 An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First Line Treatment in Caucasian Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed NCT01203917 Phase 4 Gefitinib
48 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
49 An Open Label, Single-arm Phase IV Study to Assess the Efficacy and Safety of Afatinib as Second-line Therapy for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy Completed NCT02208843 Phase 4 Afatinib
50 Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy Completed NCT01442909 Phase 4 Docetaxel and pemetrexed

Search NIH Clinical Center for Small Cell Cancer of the Lung

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cisplatin
CISPLATIN PWDR
Teniposide
Topotecan
Topotecan Hydrochloride

Cochrane evidence based reviews: small cell lung carcinoma

Genetic Tests for Small Cell Cancer of the Lung

Genetic tests related to Small Cell Cancer of the Lung:

# Genetic test Affiliating Genes
1 Small Cell Lung Carcinoma 28 RB1

Anatomical Context for Small Cell Cancer of the Lung

Organs/tissues related to Small Cell Cancer of the Lung:

FMA: Lung
MalaCards : Lung, Lymph Node, Brain, Prostate, Cervix, T Cells, Breast

Publications for Small Cell Cancer of the Lung

Articles related to Small Cell Cancer of the Lung:

(show top 50) (show all 43359)
# Title Authors PMID Year
1
Comprehensive genomic profiles of small cell lung cancer. 62 57
26168399 2015
2
Molecular profiling of small cell lung cancer in a Japanese cohort. 62 5
24657128 2014
3
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. 62 57
22941188 2012
4
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. 62 57
22941189 2012
5
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. 62 57
12629553 2003
6
Microsatellite alterations in plasma DNA of small cell lung cancer patients. 62 57
8782463 1996
7
An unusually proximal deletion on the short arm of chromosome 3 in a patient with small cell lung cancer. 62 57
1672284 1991
8
Loss of heterozygosity in a gene coding for a thyroid hormone receptor in lung cancers. 62 57
2536219 1989
9
Localization of human ERBA2 to the 3p22----3p24.1 region of chromosome 3 and variable deletion in small cell lung cancer. 62 57
2848257 1988
10
Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. 62 57
2825033 1987
11
Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. 62 57
2821398 1987
12
Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. 62 57
2821400 1987
13
Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p. 62 57
3030544 1987
14
Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. 62 57
2998591 1985
15
A 3p deletion in small cell lung carcinoma. 62 57
2982478 1985
16
Small cell carcinoma of the lung: macrophage-specific antigens suggest hemopoietic stem cell origin. 62 57
6089338 1984
17
A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC). 62 57
6286098 1982
18
Human lung small-cell carcinoma contains bombesin. 62 57
6285381 1982
19
Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). 62 57
6274023 1982
20
Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. 62 57
6265067 1981
21
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
22
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
23
Definition of a tumor suppressor locus within human chromosome 3p21-p22. 57
1438292 1992
24
Three distinct regions involved in 3p deletion in human lung cancer. 57
1347916 1992
25
Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling. 5
2594029 1989
26
Restriction fragment length polymorphism studies show consistent loss of chromosome 3p alleles in small cell lung cancer patients' tumors. 57
2900253 1988
27
Molecular genetics of lung cancer. 57
3289123 1988
28
Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. 57
2892196 1987
29
Loss of heterozygosity for a chromosome 3 sequence presumably at 3p21 in small cell lung cancer. 57
2885082 1987
30
A unique cell-surface protein phenotype distinguishes human small-cell from non-small-cell lung cancer. 57
6289311 1982
31
Neuron-specific enolase is produced by neuroendocrine tumours. 57
6111674 1981
32
Cytogenetic effects of cigarette smoke condensates in vitro and in vivo. 57
7333590 1981
33
MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. 46
20508945 2011
34
Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells. 53 62
20206622 2010
35
INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. 53 62
20420527 2010
36
ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. 53 62
20104194 2010
37
Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. 53 62
20416058 2010
38
Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumor growth. 53 62
20015838 2010
39
Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. 53 62
20179162 2010
40
Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer. 53 62
20004564 2010
41
Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas. 53 62
20398190 2010
42
Small cell carcinoma of the brain without extracranial involvement by serial CT, MRI and PET. 53 62
20224732 2010
43
Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. 53 62
19661786 2010
44
Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer. 53 62
20078550 2009
45
The diagnostic and prognostic value of ProGRP in lung cancer. 53 62
20032442 2009
46
Flow cytometric detection of small cell lung cancer cells with aberrant CD45 expression in micrometastatic bone marrow. 53 62
19674995 2009
47
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. 53 62
19887547 2009
48
Caveolin-1 is an important factor for the metastasis and proliferation of human small cell lung cancer NCI-H446 cell. 53 62
19718715 2009
49
Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. 53 62
19856060 2009
50
Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. 53 62
19679880 2009

Variations for Small Cell Cancer of the Lung

ClinVar genetic disease variations for Small Cell Cancer of the Lung:

5 (show top 50) (show all 106)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 overlap with 54 genes t(2;2)(p23;p21)(hg19 chr2:g.42552694::ochr2:g.29446394) INVERS Pathogenic
487484 GRCh37: 2:29446394-42552694
GRCh38:
2 RB1 NM_000321.3(RB1):c.2242G>T (p.Glu748Ter) SNV Pathogenic
13078 rs121913297 GRCh37: 13:49039164-49039164
GRCh38: 13:48465028-48465028
3 RB1 NM_000321.3(RB1):c.1215+1G>A SNV Pathogenic
126832 rs587776783 GRCh37: 13:48947629-48947629
GRCh38: 13:48373493-48373493
4 RB1 NM_000321.3(RB1):c.1981C>T (p.Arg661Trp) SNV Pathogenic
13087 rs137853294 GRCh37: 13:49033844-49033844
GRCh38: 13:48459708-48459708
5 TP53 NM_000546.6(TP53):c.857A>G (p.Glu286Gly) SNV Likely Pathogenic
376590 rs1057519985 GRCh37: 17:7577081-7577081
GRCh38: 17:7673763-7673763
6 TP53 NM_000546.6(TP53):c.746G>T (p.Arg249Met) SNV Likely Pathogenic
376653 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
7 TP53 NM_000546.6(TP53):c.577C>G (p.His193Asp) SNV Likely Pathogenic
376613 rs876658468 GRCh37: 17:7578272-7578272
GRCh38: 17:7674954-7674954
8 TP53 NM_000546.6(TP53):c.645T>G (p.Ser215Arg) SNV Likely Pathogenic
376661 rs1057520001 GRCh37: 17:7578204-7578204
GRCh38: 17:7674886-7674886
9 TP53 NM_000546.6(TP53):c.856G>C (p.Glu286Gln) SNV Likely Pathogenic
376591 rs786201059 GRCh37: 17:7577082-7577082
GRCh38: 17:7673764-7673764
10 TP53 NM_000546.6(TP53):c.731G>T (p.Gly244Val) SNV Likely Pathogenic
376601 rs985033810 GRCh37: 17:7577550-7577550
GRCh38: 17:7674232-7674232
11 TP53 NM_000546.6(TP53):c.820G>C (p.Val274Leu) SNV Likely Pathogenic
376678 rs1057520005 GRCh37: 17:7577118-7577118
GRCh38: 17:7673800-7673800
12 TP53 NM_000546.6(TP53):c.518T>C (p.Val173Ala) SNV Likely Pathogenic
376017 rs1057519747 GRCh37: 17:7578412-7578412
GRCh38: 17:7675094-7675094
13 TP53 NM_000546.6(TP53):c.644G>A (p.Ser215Asn) SNV Likely Pathogenic
376662 rs587782177 GRCh37: 17:7578205-7578205
GRCh38: 17:7674887-7674887
14 PTEN NM_000314.8(PTEN):c.388C>G (p.Arg130Gly) SNV Likely Pathogenic
375958 rs121909224 GRCh37: 10:89692904-89692904
GRCh38: 10:87933147-87933147
15 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln) SNV Likely Pathogenic
376244 rs121913273 GRCh37: 3:178936082-178936082
GRCh38: 3:179218294-179218294
16 PIK3CA NM_006218.4(PIK3CA):c.1625A>T (p.Glu542Val) SNV Likely Pathogenic
376474 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295
17 B2M NM_004048.4(B2M):c.2T>G (p.Met1Arg) SNV Likely Pathogenic
376372 rs1057519879 GRCh37: 15:45003746-45003746
GRCh38: 15:44711548-44711548
18 PIK3CA NM_006218.4(PIK3CA):c.1625A>G (p.Glu542Gly) SNV Likely Pathogenic
376475 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295
19 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely Pathogenic
375896 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
20 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely Pathogenic
13656 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
21 B2M NM_004048.4(B2M):c.3G>A (p.Met1Ile) SNV Likely Pathogenic
376368 rs1057519877 GRCh37: 15:45003747-45003747
GRCh38: 15:44711549-44711549
22 B2M NM_004048.4(B2M):c.1A>G (p.Met1Val) SNV Likely Pathogenic
376369 rs1023835002 GRCh37: 15:45003745-45003745
GRCh38: 15:44711547-44711547
23 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely Pathogenic
13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
24 TP53 NM_000546.6(TP53):c.517G>A (p.Val173Met) SNV Likely Pathogenic
233951 rs876660754 GRCh37: 17:7578413-7578413
GRCh38: 17:7675095-7675095
25 TP53 NM_000546.6(TP53):c.746G>A (p.Arg249Lys) SNV Likely Pathogenic
142241 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
26 TP53 NM_000546.6(TP53):c.818G>C (p.Arg273Pro) SNV Likely Pathogenic
231060 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
27 TP53 NM_000546.6(TP53):c.745A>G (p.Arg249Gly) SNV Likely Pathogenic
376654 rs587782082 GRCh37: 17:7577536-7577536
GRCh38: 17:7674218-7674218
28 TP53 NM_000546.6(TP53):c.731G>A (p.Gly244Asp) SNV Likely Pathogenic
372785 rs985033810 GRCh37: 17:7577550-7577550
GRCh38: 17:7674232-7674232
29 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely Pathogenic
12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
30 TP53 NM_000546.6(TP53):c.587G>C (p.Arg196Pro) SNV Likely Pathogenic
231165 rs483352697 GRCh37: 17:7578262-7578262
GRCh38: 17:7674944-7674944
31 TP53 NM_000546.6(TP53):c.838A>G (p.Arg280Gly) SNV Likely Pathogenic
376658 rs753660142 GRCh37: 17:7577100-7577100
GRCh38: 17:7673782-7673782
32 TP53 NM_000546.6(TP53):c.643A>G (p.Ser215Gly) SNV Likely Pathogenic
265337 rs886039484 GRCh37: 17:7578206-7578206
GRCh38: 17:7674888-7674888
33 TP53 NM_000546.6(TP53):c.839G>C (p.Arg280Thr) SNV Likely Pathogenic
12368 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
34 TP53 NM_000546.6(TP53):c.857A>C (p.Glu286Ala) SNV Likely Pathogenic
376593 rs1057519985 GRCh37: 17:7577081-7577081
GRCh38: 17:7673763-7673763
35 TP53 NM_000546.6(TP53):c.730G>C (p.Gly244Arg) SNV Likely Pathogenic
376602 rs1057519989 GRCh37: 17:7577551-7577551
GRCh38: 17:7674233-7674233
36 TP53 NM_000546.6(TP53):c.857A>T (p.Glu286Val) SNV Likely Pathogenic
376592 rs1057519985 GRCh37: 17:7577081-7577081
GRCh38: 17:7673763-7673763
37 TP53 NM_000546.6(TP53):c.374C>A (p.Thr125Lys) SNV Likely Pathogenic
216465 rs786201057 GRCh37: 17:7579313-7579313
GRCh38: 17:7675995-7675995
38 TP53 NM_000546.6(TP53):c.659A>C (p.Tyr220Ser) SNV Likely Pathogenic
12383 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
39 TP53 NM_000546.6(TP53):c.373A>C (p.Thr125Pro) SNV Likely Pathogenic
376666 rs1057520003 GRCh37: 17:7579314-7579314
GRCh38: 17:7675996-7675996
40 TP53 NM_000546.6(TP53):c.658T>G (p.Tyr220Asp) SNV Likely Pathogenic
376689 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
41 TP53 NM_000546.6(TP53):c.577C>A (p.His193Asn) SNV Likely Pathogenic
376614 rs876658468 GRCh37: 17:7578272-7578272
GRCh38: 17:7674954-7674954
42 TP53 NM_000546.6(TP53):c.839G>T (p.Arg280Ile) SNV Likely Pathogenic
161517 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
43 TP53 NM_000546.6(TP53):c.821T>A (p.Val274Asp) SNV Likely Pathogenic
376675 rs1057520006 GRCh37: 17:7577117-7577117
GRCh38: 17:7673799-7673799
44 TP53 NM_000546.6(TP53):c.518T>G (p.Val173Gly) SNV Likely Pathogenic
376016 rs1057519747 GRCh37: 17:7578412-7578412
GRCh38: 17:7675094-7675094
45 RB1 NM_000321.3(RB1):c.2117G>T (p.Cys706Phe) SNV Likely Pathogenic
376330 rs121913295 GRCh37: 13:49037877-49037877
GRCh38: 13:48463741-48463741
46 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp) SNV Likely Pathogenic
217293 rs121913275 GRCh37: 3:178936093-178936093
GRCh38: 3:179218305-179218305
47 B2M NM_004048.4(B2M):c.1A>T (p.Met1Leu) SNV Likely Pathogenic
376370 rs1023835002 GRCh37: 15:45003745-45003745
GRCh38: 15:44711547-44711547
48 B2M NM_004048.4(B2M):c.2T>C (p.Met1Thr) SNV Likely Pathogenic
376371 rs1057519879 GRCh37: 15:45003746-45003746
GRCh38: 15:44711548-44711548
49 AKT1 NM_001382430.1(AKT1):c.49G>A (p.Glu17Lys) SNV Likely Pathogenic
13983 rs121434592 GRCh37: 14:105246551-105246551
GRCh38: 14:104780214-104780214
50 PIK3CA NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala) SNV Likely Pathogenic
376473 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295

Copy number variations for Small Cell Cancer of the Lung from CNVD:

6 (show top 50) (show all 515)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 15909 1 120235683 147296355 Substitutions and indels small cell lung cancer
2 18774 1 147306435 159745095 Substitutions and indels small cell lung cancer
3 21590 1 159753915 159864147 Substitutions and indels small cell lung cancer
4 21631 1 159879159 167481135 Substitutions and indels small cell lung cancer
5 22562 1 167488767 167515635 Substitutions and indels small cell lung cancer
6 22575 1 167524383 182844003 Substitutions and indels small cell lung cancer
7 22643 1 16801095 16840107 Substitutions and indels small cell lung cancer
8 22724 1 16861959 29150031 Substitutions and indels small cell lung cancer
9 24621 1 182849019 182888703 Substitutions and indels small cell lung cancer
10 24623 1 182893695 194979795 Substitutions and indels small cell lung cancer
11 25853 1 194993223 195074031 Substitutions and indels small cell lung cancer
12 25942 1 195088143 205083387 Substitutions and indels small cell lung cancer
13 27160 1 205088907 205109547 Substitutions and indels small cell lung cancer
14 27163 1 205114395 208124379 Substitutions and indels small cell lung cancer
15 27411 1 208129227 208155879 Substitutions and indels small cell lung cancer
16 27424 1 208162923 222138663 Substitutions and indels small cell lung cancer
17 28412 1 222150063 222281979 Substitutions and indels small cell lung cancer
18 28435 1 222297471 247249719 Substitutions and indels small cell lung cancer
19 31650 1 29155527 30043083 Substitutions and indels small cell lung cancer
20 31718 1 30048807 41173191 Substitutions and indels small cell lung cancer
21 32828 1 39746 16783059 Substitutions and indels small cell lung cancer
22 33011 1 41174800 41175800 Intrachromosomal rearrangement small cell lung cancer
23 33013 1 41178543 42371163 Substitutions and indels small cell lung cancer
24 33099 1 42374208 42375208 Intrachromosomal rearrangement small cell lung cancer
25 33100 1 42376011 42579327 Substitutions and indels small cell lung cancer
26 33116 1 42583395 42584395 Intrachromosomal rearrangement small cell lung cancer
27 33117 1 42584427 44255643 Substitutions and indels small cell lung cancer
28 33294 1 44259752 44260752 Intrachromosomal rearrangement small cell lung cancer
29 33295 1 44260511 44261511 Intrachromosomal rearrangement small cell lung cancer
30 33296 1 44260527 44275323 Substitutions and indels small cell lung cancer
31 33300 1 44279330 44280330 Intrachromosomal rearrangement small cell lung cancer
32 33301 1 44279742 44280742 Intrachromosomal rearrangement small cell lung cancer
33 33302 1 44280303 48578211 Substitutions and indels small cell lung cancer
34 33819 1 48580747 48581747 Intrachromosomal rearrangement small cell lung cancer
35 33821 1 48583227 51275739 Substitutions and indels small cell lung cancer
36 33980 1 51279608 51280608 Intrachromosomal rearrangement small cell lung cancer
37 33981 1 51281079 54467547 Substitutions and indels small cell lung cancer
38 34296 1 54469360 54470360 Intrachromosomal rearrangement small cell lung cancer
39 34297 1 54473247 54557103 Substitutions and indels small cell lung cancer
40 34301 1 54561497 54562497 Intrachromosomal rearrangement small cell lung cancer
41 34302 1 54562083 54649251 Substitutions and indels small cell lung cancer
42 34322 1 54652634 54653634 Intrachromosomal rearrangement small cell lung cancer
43 34323 1 54654159 57627915 Substitutions and indels small cell lung cancer
44 34908 1 57632775 57657135 Substitutions and indels small cell lung cancer
45 34910 1 57661947 72536187 Substitutions and indels small cell lung cancer
46 36221 1 72541191 72583059 Substitutions and indels small cell lung cancer
47 36257 1 72587919 85749039 Substitutions and indels small cell lung cancer
48 37122 1 85755495 85774959 Substitutions and indels small cell lung cancer
49 37129 1 85779879 120230763 Substitutions and indels small cell lung cancer
50 41421 10 17866791 18173655 Substitutions and indels small cell lung cancer

Expression for Small Cell Cancer of the Lung

Search GEO for disease gene expression data for Small Cell Cancer of the Lung.

Pathways for Small Cell Cancer of the Lung

Pathways related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.61 TP53 RB1 PTEN PIK3CA AKT1
2
Show member pathways
12.37 TP53 PTEN PIK3CA AKT1
3
Show member pathways
12.23 TP53 RB1 PTEN PIK3CA AKT1
4
Show member pathways
12.16 TP53 PTEN PIK3CA AKT1
5
Show member pathways
12.09 TP53 RB1 PTEN AKT1
6
Show member pathways
12.04 TP53 RB1 PTEN PIK3CA AKT1
7
Show member pathways
12.02 TP53 PTEN PIK3CA AKT1
8 12 AKT1 PTEN RB1 TP53
9 11.93 SYP PTEN NCAM1 AKT1
10 11.9 TP73 TP53 RB1 PTEN
11 11.79 PTEN PIK3CA AKT1
12 11.75 TP53 PTEN AKT1
13 11.74 PTEN ENO2 AKT1
14
Show member pathways
11.7 TP53 PIK3CA AKT1
15 11.68 TP73 TP53 PTEN PIK3CA
16
Show member pathways
11.61 TP53 PIK3CA AKT1
17 11.59 PTEN PIK3CA AKT1
18 11.54 AKT1 PIK3CA RB1
19 11.48 PIK3CA NCAM1 AKT1
20 11.46 TP53 PIK3CA AKT1
21 11.42 TP53 PTEN PIK3CA AKT1
22 11.39 PTEN PIK3CA AKT1
23 11.34 TP53 RB1 PTEN PIK3CA AKT1
24
Show member pathways
11.32 TP53 PTEN PIK3CA AKT1
25 11.13 PTEN PIK3CA AKT1
26 11.07 PTEN PIK3CA AKT1
27 11.04 TP53 RB1 PTEN AKT1
28 10.88 TP53 RB1 PTEN PIK3CA AKT1
29 10.73 PIK3CA AKT1
30 10.58 TP53 AKT1
31 10.52 TP53 RB1

GO Terms for Small Cell Cancer of the Lung

Biological processes related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.92 TP53 RB1 PIK3CA MIR21 AKT1
2 phosphatidylinositol 3-kinase signaling GO:0014065 9.73 PTEN PIK3CA AKT1
3 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.46 GRP CHGA
4 cellular response to decreased oxygen levels GO:0036294 9.13 PTEN AKT1
5 negative regulation of mitotic cell cycle GO:0045930 8.8 TP53 RB1 MIR21

Molecular functions related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.36 TP53 RB1 PTEN NKX2-1 ENO2 AKT1

Sources for Small Cell Cancer of the Lung

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....